This week, Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche ...
Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Investor's Business Daily on MSN2h
Stock Market Correction: Trump Tariffs Triggers Sell-Off Despite Tame Inflation: Weekly ReviewThe major indexes suffered another week of sharp losses as Trump tariffs ramped up, shrugging off tame inflation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback